Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation.

TitleNovel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation.
Publication TypeJournal Article
Year of Publication2021
AuthorsKim, HT, Logan, B, Weisdorf, DJ
JournalTransplant Cell Ther
Date Published2021 08
KeywordsHematopoietic Stem Cell Transplantation, Retrospective Studies, United States

With the recent development of transplant-specific composite endpoints for evaluation of allogeneic hematopoietic cell transplantation (alloHCT) outcomes, the use of these novel endpoints is growing rapidly. Combining multiple endpoints into a single endpoint, these composite endpoints appear simple and can be used as a summary measure for overall effectiveness of an intervention. However, all component endpoints may not have equal clinical significance, and an intervention may not work proportionally in the same direction for all components of a composite endpoint. This may complicate the interpretation of results, particularly if there are opposing effects of differing component endpoints. We assess the benefits and limitations of various composite endpoints used in alloHCT studies recently and propose guidelines for their use and interpretation. © 2021 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Alternate JournalTransplant Cell Ther
PubMed ID34004355
PubMed Central IDPMC8489461
Grant ListP01 CA229092 / CA / NCI NIH HHS / United States
U10 HL069294 / HL / NHLBI NIH HHS / United States